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Abstract
Purpose: In the United Kingdom (UK), the National Health Service (NHS) Diabetic Eye
ScreeningProgramoers an annual eye examination to all peoplewith diabetes aged
12 and over aimed at the early detection of people at high risk of visual loss due to
diabetic retinopathy. The purpose of this study was to design a model for predicting
patients at risk of developing retinopathy using patient characteristics and clinical
measurements.
Methods: We appraised data collected from the population-based Diabetic Eye
Screening Program in East Anglia between 2011 and 2016. The data comprised reti-
nal photographic screening results, patient characteristics of gender and age of the
subject as well as duration and type of diabetes, and routine biochemical measures
of Hemoglobin A1c (HbA1c), blood pressure, Albumin to Creatinine ratio (ACR), es-
timated Glomerular Filtration rate (eGFR), serum creatinine, cholesterol, and Body
Mass Index (BMI). Individuals were classified according to the presence or absence
of retinopathy as indicated by their retinal photographic screening results. A logistic
regression with Least Absolute Shrinkage and Selection Operator (lasso) regulariza-
tion, random forest, gradient boosting machine, and regularized gradient boosting
model were deployed and cross-validated for their predictive ability.
Results: A total of 6375 subjects with recorded information for all available biochem-
ical measures were identified from the cohorts. Of these, 5969 individuals had no
signs of diabetic retinopathy. Of the remaining 406 individuals with signs of diabetic
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retinopathy, 352 had background diabetic retinopathy and 54 had referable diabetic
retinopathy. The highest value of the ten-fold cross-validated area under the curve
(AUC) of the receiver operating curve (ROC), 0.73 ± 0.03, was achieved by the gradient
boosting machine and the minimum required set of variables to yield this perfor-
mance included: duration of diabetes, HbA1c, ACR, and age. A subsequent analysis
on the predictive power of the biochemical measures showed that when HbA1c and
ACR measurements were available for longer time periods, the performance of the
models was enhanced. When HbA1c and ACR measurements for a five-year period
prior to the event of studywere available, gradient boostingmachine cross-validated
AUC was 0.77 ± 0.04 in comparison to the cross-validated AUC of 0.68 ± 0.04 when
only information for the one-year period for these variables was available. Similarly,
an increment from 0.70 ± 0.02 to 0.75 ± 0.04 was observed with random forest. The
dataset with the one-year measurements comprised 4857 subjects, of whom 4572
had no retinopathy and the remaining 285 had signs of retinopathy. The dataset with
the five-year measurements comprised 757 subjects, of whom 696 had no retinopa-
thy and the remaining 51 had signs of retinopathy.
Conclusion: Patient information and routine biochemical measures can be used to
identify patients at risk of developing retinopathy with a significant reduction of the
number of screening visits.
Keywords: area under the ROC curve (AUC), classification, gradient boosting, lasso,
prevalence and risk of diabetic retinopathy, random forest, retinal screening
1. Introduction
Diabetic retinopathy and diabeticmaculopathy are themost commonmicrovascular
complications of diabetes and among the leading causes of blindness in the UK.1 Dia-
betic retinopathyaccounts for about7%ofpeoplewhoare registeredblind inEngland
and Wales.2,3
The Diabetic Eye Screening Program in the UK has been in place for over a decade
and recommends an annual eye examination to all people diagnosed with diabetes
aged 12 and over. The principal goal of the program is to prevent diabetes-related
blindness, with individuals identified at high risk being referred to eye clinics for fur-
ther assessment andmanagement.4 Since 1996, the number of people with diabetes
in the UK has more than doubled from 1.4 million to 3.3 million.2,5 In England alone,
there are∼ 2.8 million people living with diabetes,2 the majority of whom (99%) are
eligible for screening.6
Examination of the retinal grading outcomes of people attending the population-
based Diabetic Eye Screening Service in East Anglia showed that the majority of
people had no retinopathy. There are∼ 90,000 people screened by the Diabetic Eye
Screening Service in East Anglia on an annual basis, whose retinal photographic im-
ages are assessed through a quality-assured multi-level grading scheme compliant
with national recommendations.7 The prevalence of diabetic retinopathy was cal-
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culated for the years 2011 to 2016 for all people with given consent and assessable
retinal images. Table 1 shows the prevalence of diabetic retinopathy per year.
Table 1. Prevalenceof diabetic retinopathy in thepopulation-basedDiabetic EyeScreeningPro-
gram in East Anglia.
2011∗ 2012 2013 2014 2015 2016∗
N =
28,042
N =
68,447
N =
75,417
N =
82,209
N =
83,767
N =
21,931
No
retinopathy
0.70 0.70 0.72 0.71 0.71 0.70
Background
retinopathy
0.26 0.26 0.24 0.26 0.26 0.26
Referable
retinopathy
0.04 0.04 0.04 0.03 0.03 0.04
∗For the years 2011 and 2016, information was available for the second half of 2011
and the first trimester of 2016.
Over the years, 70-72% of the population screened annually were graded with
no retinopathy, 24-26% were graded with background retinopathy, and 3-4% were
graded with referable retinopathy. Similar prevalence of diabetic retinopathy is also
reported from other screening services across the UK.8–10 These figures imply that an
annual recall for screening of all patients with diabetes may not be the optimal ap-
proach.
In this study, weused longitudinal data of patient characteristics andbiochemical
measures from the population-based Diabetic Eye Screening Service in East Anglia to
build a model for predicting the presence/absence of diabetic retinopathy. Eective
identification has the potential to save on patients’ traveling costs and time without
compromising their health. It can additionally reduce the workload of screening ser-
vices and save on healthcare resources, something which has become of utmost im-
portance due to the ever-increasing number of patients with diabetes.11
2.Methods
Data comprised retinal photographic screening results, patient characteristics of
gender and age of the subject as well as duration and type of diabetes, and routine
biochemical measures of Hemoglobin A1c (HbA1c), blood pressure, Albumin to Cre-
atinine ratio (ACR), estimated Glomerular Filtration rate (eGFR), serum creatinine,
cholesterol, and Body Mass Index (BMI).
72 E. Kotsiliti et al.
Retinal photographic screening results and patient characteristics were extracted
in an anonymized manner from the population-based Diabetic Eye Screening Pro-
gram in East Anglia between 01/07/2011 and 31/03/2016 for subjects with given con-
sent. Subjects invited to the retinal screening program include all people with dia-
betes aged≥ 12 years. There were 104,366 subjects who attended the service within
that period. The median number of screening episodes was 4 (interquartile range 2-
5). At each screening episode, two color retinal images of standard 45o fields (macula
and disc centered) were taken per eye aer pupil dilatation. The retinal images were
subsequently assessed by accredited personnel who assigned grades for the pres-
ence and severity of diabetic retinopathy via a quality-assured multi-level scheme
that meets national standards.7
Grades assigned include R0 for no retinopathy, R1 for background retinopathy, R2
for non-proliferative retinopathy, R3a for active proliferative retinopathy, R3s for sta-
ble proliferative retinopathy, and M1 for maculopathy. Subjects with R0, R3s, and R1
are invited for annual re-screen, and in the latter case, the General Practice is also
notified so that these people can be advised of appropriate actions to limit risk of
disease progression. Subjects with R2, R3a, and/or M1 (hereaer referred to as refer-
able grades) are referred to ophthalmology clinics for further assessment and man-
agement. Detailed information regarding the feature-based grading criteria and re-
lationship to the Early Treatment Diabetic Retinopathy Study (ETDRS) severity scale
can be found on the Diabetic Eye Screening Programwebsite.12
For the subjects who attended the screening service within that period, measure-
ments of dierent biochemical measures were also extracted. These measurements
were taken for each subject during their routine checks at the GP practices as part
of their diabetes care. The number of measurements and the time period over which
theywere takenvariedamong subjects. Theannual numberofmeasurements ranged
fromone to four, and the timehorizon overwhich theywere taken extended fromone
up to ten years prior to the last retinal screening appointment. Therefore, the mul-
tiple measurements of each biochemical measure were averaged before they were
inserted into the models.
Subjectswere categorized into two groups, no retinopathy (NR) and any retinopa-
thy (AR), based on the results from the retinal photographic images (retinal grades)
and aer meeting certain requirements.
Subjects included in theNR grouphad at least three eye examinations resulting in
R0. The minimum number of eye examinations was set at three to minimize the im-
pactof possiblemisclassificationerrors in thegradingprocess. For example, a subject
with a grading pattern of ‘R0 - R0 - R0’, increased our confidence that the subject was
indeed free of retinopathy during the second examination in comparison to a sub-
ject with a pattern of ‘R0 - R0 - R1’. The last grade was only used as a reassurance
grade for the absence of retinopathy, and therefore, the clinical profile of included
subjects was up to the screening date before the last. This requirement has led to
the exclusion of subjects with transient patterns between R0 and R1 (i.e., R0 – R1 –
R0). Longitudinal examination of the grading outcomes in the data showed a consid-
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erable number of subjects with such transient patterns. For those of short grading
history, e.g., two or three grading outcomes, it was impossible to conclude whether
these patterns resulted from over-grading or under-grading. Possible factors to such
patterns are the variability of human performance, confusion of photographic arti-
facts, andmedia opacity and sensitivity of fundus photography to depict changes oc-
curring deep in the retina. Similar observations were also reported from the Scottish
Diabetic Eye Screening Program,13 where 18.2% of people with type 1 diabetes and
36.4%of peoplewith type 2 diabetes transitioned frommild background retinopathy
to no visible retinopathy at their subsequent examination.
Subjects included in the AR group met any of the following two sets of require-
ments.
1. Set 1: At least four eye examinations of the pattern ‘R0 - R0 - . . . - R1 - R1 orworse’.
This set aims to capture the subjects with onset of retinopathy (R1). The subsequent
grading outcome aer R1 serves only as a reassurance grade, and therefore, the clini-
cal profile of the included subjectswas up to the first R1 event. The reassurance grade
needs to be R1 or worse, and therefore subjects with a pattern of ‘R0 - R0 - . . . - R1 -
R0’ were excluded, as in that case, it would be impossible to judge whether subjects
were under-graded at the last event or over-graded at the event prior to the last.
2. Set 2: At least three eye examinations, the last of which resulted to a referable
grade and all grades prior to that were R0. Here, no reassurance grade was required
because: a) referable grades were assigned by the graders at the top level of the hier-
archy, who we assumed to have optimal performance; and b) a subsequent grade of
R0 could be attributable to subjects possibly being treated aer referral to the hospi-
tal. Subjects with evidence of previous laser treatment or unassessable images were
excluded from both groups.
To utilize all available biochemical measures, only subjects with a complete clin-
ical profile were included in the study. This resulted in 5969 subjects in the NR group
and 406 subjects in the AR group. Of the 406 subjects in the AR group, 352 had R1 and
the other 54 had referable diabetic retinopathy. The characteristics of the population
included in the study are shown in Table 2 and Table 3.
Table 2. Patient characteristics (categorical variables) of the 5969 subjects in the NR group and
406 subjects included in the AR group.
NR = 5969 AR = 406
Gender (male) 57% 51%∗
Diabetes Type (type 2) 96% 95%
∗Statistical significance (p< 0.05). Tested with the Chi-squared test.
The transformed features that were extracted from the various biochemical mea-
surements were considered for the time period prior to the event of study, and the
74 E. Kotsiliti et al.
Table 3. Patient characteristics (continuous variables) of the 5,969 subjects in theNRgroup and
406 subjects included in the AR group.
Median (25th 75th centile)
NR = 5969 AR = 406
Age (years) 68 (60-76) 70 (59 78)∗
Duration of diabetes (years) 7 (3-11) 9 (6-13)∗
HbA1c (mmol/mol) 54 (48-61) 59 (53-68)∗
Systolic blood pressure (mmHg) 133 (128-138) 133 (128-138)∗
Cholesterol (mmol/L) 4.6 (4.0-5.1) 4.5 (4.0-5.0)∗
Serum Creatinine (mmol/L) 86 (76-98) 85 (75-97)∗
ACR (mg/mmol) 1.01 (0.9-1.8) 1.40 (1.0-2.8)∗
eGFR (mL/min/1.73m2) 78 (67-88) 79 (68-87)∗
BMI (kg/m2) 30.5 (27.1-34.6) 30.2 (26.9-34.5)∗
∗Statistical significance (p< 0.05). Tested with the Mann-Whitney U test.
features related to thepatient characteristicswere consideredat thedateof the event
of study. These featureswere investigated for their ability to separatebetweenNRand
AR.
Both linear and non-linear techniques were deployed and compared for their
predictive ability. These comprised logistic regression with lasso regularization,14,15
random forest,16 gradient boosting machine,17 and extreme or regularized gradient
boosting machine.18
Lasso regularized logistic regression has shown good performance in the pres-
ence of many irrelevant features,19 and can perform feature selection via the lasso
penalty term. Selecting a good value for the lasso penalty is critical and the process
for selecting it is described later in this section.
Random forest, gradient boosting machine, and extreme or regularized gradient
boostingmachine are decision tree ensemblemodelswhich involve a combination of
a large number of trees. In a random forest, several decision trees are built on boot-
strapped training samples, andeach timea split in a tree is considered, only a random
subset of the predictors is chosen as split candidates from the full set of predictors.
This process leads to the decorrelation of the built trees, therebymaking the average
of the resulting trees less variable and hence more reliable. In a gradient boosting
machine, the trees are grown sequentially. In more detail, each tree is grown using
information from previously grown trees in order tominimize a loss function. A regu-
larization term is also involved and controls the rate at which boosting learns. In gen-
eral, statistical learningapproaches that learn slowly tend toperformwell. Extremeor
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regularized gradient boosting machine works in a similar way as the gradient boost-
ing machine, but there are dierences in the modeling details of the regularization
term. These tree ensembles can oen result in dramatic improvements in prediction
accuracy over a single decision tree, and were deployed due to the dierences in the
underlying modeling principles and the varying number of parameters involved, the
tuning of which could have a considerable impact on the predictive performance.
The predictive performance of eachmodel was assessed by the AUC value on un-
seen data. To create the unseen data from the existing set of observations, a ten-fold
cross validation approach was deployed that suers neither from excessively high
bias nor from very high variance in comparison to the validation and leave-one-out
approaches.20
Parameter tuning was performed during the model fitting phase with the use of
five-fold cross validation. In more detail, the train set was further divided into five
folds, one of which was treated as a test set, and the remainder as train set. To avoid
confusion,we refer to these sub-divided sets as internal train and test sets. The choice
of five foldswasdue to the limitednumber of training samples. For each internal train
set, a grid of values for the tuning parameter(s) was supplied, and for each of those
values or combination of them, the model was fitted. Subsequently, the model was
assessed on the internal test set by estimating the AUC. The value or combination of
values of the tuning parameter(s) that maximized the internal test set AUC rendered
a candidate value. The sameprocesswas repeated across all folds, and the candidate
values that were chosenmost frequently formed the final optimal values.
In the lasso regularized logistic regression, variable selection is inherently per-
formed during parameter tuning, due to the fact that the parameter has the eect
of shrinking the coeicient estimated values towards zero and forcing some of them
tobeexactly equal to zerowhena suiciently large value is selected. In the caseof the
tree-based models, a backward stepwise variable selection approach was followed.
Initially, themodels were trained on the full set of features and their predictive ability
was assessed on the test set by estimating the AUC. At the next step, the variable with
the lowest mean decrease in Gini index (a measure of node purity) was eliminated
and the model was trained and assessed on the test set for the remainder set of pre-
dictors. The process was repeated until only one feature remained. All analyses were
performed in R Statistical Computing soware.21
Given the fact that the number of measurements for the biochemical measures
as well as the time window over which they were taken varied among subjects, we
subsequently conducted an analysis to investigate whether the utilization of clinical
information for shorter and longer periods of time would impact the performance of
the models. Initially, univariate logistic regression was deployed to assess the pre-
dictive power of each biochemical measure at dierent time windows. The averaged
value of the measurements at each observational time window was used as input in
themodel. Time windows ranged from one up to ten years before the event of study.
The predictive power was assessed in the context of ten-fold cross-validated AUC.
Thebest independentpredictors, i.e., those that yielded thehighest cross-validated
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AUC (and above 0.5), were HbA1c and ACR. At the subsequent step, these predictors
were used to form two datasets. Both datasets included the entire set of predictors,
but in one dataset the measurements of HbA1c and ACR were only available for the
one-year period prior to the event of study, whereas in the other the measurements
of HbA1c and ACR were available for the five-year period prior to the event of study.
The five-year period was the maximum period of time we could consider to form the
second dataset, since, aer this year, only a few subjects had a full clinical record of
the entire set of predictors. The dataset with the one-year measurements comprised
4857 subjects, of whom 4572 had no retinopathy, while the remaining 285 had signs
of retinopathy. The datasetwith the five-yearmeasurements comprised 757 subjects,
of whom 696 had no retinopathy and the remaining 51 had signs of retinopathy.
Gradient boostingmachine and random forest were deployed in both datasets to
quantify the impact that the exploitation of HbA1c and ACR information for longer
periods of time could have on the models’ predictive ability. Gradient boosting ma-
chine was deployed due to the fact that it yielded the best predictive performance in
the previous experiment, and the latter in order to investigate whether there was a
consistency in the outcomes between the two learning techniques.
Given the small number of subjects belonging to the retinopathy group, particu-
larly in the five-year dataset, five-fold cross validation was used instead of ten-fold
cross validation in this experiment to assess predictive performance. Parameter tun-
ing and feature selection were performed in the same way as described previously.
3.Results
Logistic regression with lasso regularization, random forest, gradient boosting ma-
chine, and extreme or regularized gradient boosting machine were fitted on the
dataset comprising 5969 individuals with no signs of diabetic retinopathy and 406
individuals with signs of diabetic retinopathy. For these individuals, measurements
for the entire set of biochemical measures were available. The available measure-
ments were averaged prior to inclusion in the models; therefore, the entire set of
features/predictors comprised 11 variables: the mean value of measurements for
each biochemical measure and the value for each of the patient’s characteristics.
Gradient boosting machine had the best performance with 0.73 for the cross-
validated AUC and standard deviation of 0.03 (0.73 ± 0.03). The minimum subset of
variables to yield that performance included four variables: diabetes duration, mean
value of HbA1c measurements, mean value of ACR measurements, and subject age.
The performance of the model was stabilized to AUC 0.73 ± 0.03 for all subsequent
subsets of variables. The model of four variables yielded an AUC increment of 0.01
and lower standard deviation over the model of three variables, which comprised
duration of diabetes, HbA1c, and ACR.
Random forest and regularized gradient boosting yielded an AUC of 0.72 ± 0.05
and0.72 ±0.04, respectively. Thebest performancewas achieved for the same subset
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of variables as in gradient boosting, and it remained the same or slightly changed (±
0.01) for the subsequent sets of variables.
The lasso regularized logistic regression had an inferior performance over the rest
of the models with an AUC 0.70 ± 0.02. In all ten folds, the lasso regularized logistic
regression consistently selected a set of three variables: duration of diabetes, mean
value of HbA1c measurements, and mean value of ACR measurements. The coei-
cientsofall predictor variableswerepositive,meaning that subjectswithhighermean
values of HbA1c and ACR as well as longer duration of diabetes are more likely to de-
velop diabetic retinopathy. These findings of HbA1c and duration of diabetes are in
concordance with the findings of major epidemiological studies.22–24
Figure 1 displays the mean value of the ten-fold cross-validated AUC for the ran-
dom forest, gradient boostingmachine, and regularized gradient boostingmodels by
the number of variables which remained in the model at each step of backward fea-
ture selection.
Fig. 1. Mean value of the ten-fold cross-validated AUC for random forest, gradient boostingma-
chine, and regularizedgradient boostingmachine for dierent sets of variables formedby step-
wise backward selection.
Subsequently, univariate logistic regression was deployed to compare the inde-
pendent predictive power of each biochemical measure for time-varying observa-
tional windows. The observational timewindows ranged from one up to amaximum
of ten yearsprior to the event of study (measurements of somebiochemicalmeasures
were available for longer time periods than others). The predictive power was as-
sessed in the context of ten-fold cross-validated AUC, and the results are represented
in Table 4.
As can be seen in Table 4, the best independent predictors for all biochemical
measures, i.e., those that yielded the highest value of AUC, were HbA1c and ACR. In
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more detail, the ten-fold cross-validated AUC for HbA1c gradually increased from0.62
to 0.66 for longer time periods, and a gradual increment from 0.60 to 0.68 was also
observed in the case of ACR. The predictive power of the remaining variables was
poor, i.e., AUC ∼ 0.50, and most of them did not seem to be aected by the vary-
ing time windows. An inverse eect of longer time windows on the predictive power
of systolic blood pressure and cholesterol was observed. In particular, the ten-fold
cross-validated AUC for systolic blood pressure gradually decreased from0.54 to 0.51
for longer time periods; a gradual decrement from 0.55 to 0.43 was also observed in
the case of cholesterol.
Since HbA1c and ACR were the most significant independent clinical predictors,
showing improved predictive power for longer observational time windows, mod-
els were subsequently re-fitted into two newly formed datasets in which the mea-
surements of these two predictors were available for a one-year and five-year period
of time, respectively. The remaining clinical predictors were also included in these
datasets, but the extent of their measurements was not constrained to a particular
limit of time. The dataset with the one-yearmeasurements comprised 4857 subjects,
of whom 4572 had no retinopathy and the remaining 285 had signs of retinopathy.
The dataset with the five-year measurements comprised 757 subjects, of whom 696
subjects had no retinopathy and the remaining 51 had signs of retinopathy.
Gradientboostingmachineand randomforestwere fitted inbothdatasetsand the
results of the five-fold cross-validated AUC are displayed in Figure 2. In both models,
predictive ability was improved for the five-year dataset in comparison to the one-
year dataset. In particular, gradient boosting machine yielded an increment of the
five-fold cross-validated AUC from 0.68 ± 0.04 for the one-year dataset to 0.77 ± 0.04
for the five-year dataset. Similarly, random forest yielded an increment of the five-
fold cross-validated AUC from 0.70 ± 0.02 for the one-year dataset to 0.75 ± 0.04 for
the five-year dataset.
Fig. 2. The five-fold values of AUC for the one-year and year-year datasets. The figure on the
le shows the values of AUC yielded by random forest; the one on the right shows the values of
AUC yielded by gradient boosting machine.
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4.Discussion
This study explored the potential for predicting the risk of developing diabetic
retinopathy with the use of patient characteristics and clinical biochemical mea-
sures. Of all models considered in the analysis, gradient boosting machine had the
best predictive ability, yielding an AUC of 0.73 ± 0.03. In addition, all non-linear mod-
els yielded better predictive ability than the linear model, indicating that there could
be amore complex underlying relationship between the predictors and the response
that the linear model failed to capture.
The model that yielded the best predictive performance included the following
variables: patient age, diabetes duration, mean value of HbA1c measurements, and
mean value of ACR measurements. Epidemiological studies have reported the ef-
fect of age, duration of diabetes, and HbA1c on the incidence and progression of di-
abetic retinopathy.24–28 The Diabetes Control and Complications Trial (DCCT)24 and
the United Kingdom Prospective Diabetes Study (UKPDS)25 have demonstrated that
improved blood glucose control reduced the risk of developing diabetic retinopa-
thy. This is in concordance to our finding of improved predictive power of HbA1c for
longer observational timewindows, due to the fact that the extendedmeasurements
of HbA1c provide an indication of prolonged poor or good glycemic control. Our find-
ing that ACR is a significant predictor for diabetic retinopathy is in agreement with
the findings of Yanming et al.28 that ACR plays an important role in the pathogene-
sis of diabetic retinopathy. Moreover, we found that the predictive ability of ACR was
improved when measurements were available for longer periods of time prior to the
event of study.
The remainingbiochemicalmeasures (systolic bloodpressure, cholesterol, serum
creatinine, eGFR, and BMI) were not included in our final model due to their poor
predictive ability. Although associations of diabetic retinopathy with these variables
have been documented by several studies,25,29–36 findings were inconsistent and a
definitive correlation between them and the incidence and progression of diabetic
retinopathy has not been established. Even when longer measurement periods for
these variables were considered in the present study, their predictive ability did not
show any improvement. On the contrary, in the case of systolic blood pressure and
cholesterol, an adverse eect was observed. A comprehensive review about blood
pressure control for diabetic retinopathy by Do et al.37 concluded that the available
evidence supports a beneficial eect of intervention to reduce blood pressure with
respect to preventing diabetic retinopathy for up to four to five years. Additionally, it
stated that the existing evidenceweakens the conclusion regarding an overall benefit
of intervening on blood pressure solely to prevent diabetic retinopathy. These con-
clusions shed some light on the declining predictive ability of systolic blood pressure
on the development of diabetic retinopathy for longer observational time windows
thatwasobserved in thepresent study. SystolicbloodpressureyieldedanAUCof0.54
for the one-year up to the three-year observational timewindows, and then gradually
deteriorated reaching an AUCof 0.51 for the ten-year observational timewindow. The
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deteriorating predictive ability of cholesterol for increasing time windows requires
further exploration due to the number of factors that might aect cholesterol levels.
Other studies focused on the risk assessment of diabetic retinopathy were found
in the literature.38–42 Cichosz et al.38 developed a model for the identification of pa-
tients at high risk of having retinopathy at the time they were diagnosed with type 2
diabetes. The model yielded an AUC of 0.74, but it required additional information
on the following variables: BMI, waist circumference, systolic blood pressure, urinary
albumin, andurinary creatinine. In addition, themodelwas validatedona small sam-
ple and the stability of predictive performance (e.g., standard deviation) was not re-
ported. Moreover, this model could only be applicable to patients with newly diag-
nosed type 2 diabetes.
The remaining studies had a dierent design aiming at the identification of pa-
tients at high risk of developing referable diabetic retinopathy andusedadditional in-
formation on the presence and severity of diabetic retinopathy at previous screening
appointments. Therefore, these models could not be applicable to detect the onset
of diabetic retinopathy and they additionally require information on past screen-
ing grading outcomes. Mehlsen et al.39 presented a model with which, on average,
the screening interval could be prolonged by approximately 2.9 times in patients
with type 1 diabetes, and by 1.2 times in patients with type 2 diabetes. This model,
apart from clinical information, also requires information on the recorded severity
of diabetic retinopathy, which is expressed by the number of retinal hemorrhages
and hard exudates counted in macula-centred 60° fundus photographs. Aspelund et
al.40,41 developed a model which required information on the presence and severity
of retinopathy at the last screening appointment. This model yielded an AUC of 0.80
(CI 0.78 to 0.81) for patientswith type 2 diabetes, and 0.70 (CI 0.67 to 0.73) for patients
with type 1 diabetes. Scanlon et al.42 presented amodel which yielded an AUCof 0.80
and also required information on the presence and severity of diabetic retinopathy
at the last screening appointment.
As these models were not directly comparable to the model in the present study
due to their dierent scope, design, and presentation of results (i.e., AUC was not re-
ported in some cases), we decided to investigate how the model in our study per-
formed on patients with R1 and referable retinopathy separately. We chose gradient
boostingmachine to assess performance andwe selected anoverall threshold for the
model in order to categorize the subjects into one of the two groups. The classifica-
tion results were aggregated for the ten folds. For a very small value of the threshold,
11 out of 352 subjects with R1 were misclassified as R0 (3% error) and 2 out of 54 with
referable retinopathy (4% error) were misclassified as R0. This, however, decreased
the specificity of themodel to 20%, which, if considered for the 90,000 population in
the East Anglia screening program, could still lead to ∼ 17,000 less screening visits.
When a bigger threshold value was applied, specificity increased to 46% (∼ 40,000
less screening visits), 17 out of 352 subjects with R1weremisclassified as R0 (5% error
rate) and 10 out of 54 with referable retinopathy (19% error rate) were misclassified
as R0.
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Threshold values, however, can be determined on the basis of acceptable error
for the referable grades, which, based on the findings of major clinical trials, should
be low. In brief, the findings from the large clinical trials are the following: the an-
nual risk of progressing from R1 to R2 and/or R3 is ∼ 8% for people who receive no
medical intervention,24 the annual risk of progressing from R2 to R3 is 20% for peo-
plewith type 2 diabetes if le untreated,43 and untreated eyeswith R3 characteristics
have a risk of 15.9% − 26% of progressing to severe visual loss within two years.44
These figures suggest that patients with referable retinopathy have at least a 2.5-fold
higher risk to vision loss/deterioration than patients with R1, and somisclassification
error for these people shall be really low. An exception for the case of R1M1 could be
applied by allowing a bigger margin of error in the face of the findings of the study45
which reported that only 10% of the recorded M1 represent clinically significant mac-
ular edema requiring treatment.
We have shown how a model exploiting patient characteristics and biochemical
measures can be used to identify patients at risk of developing retinopathy. Eective
identification could reduce the number of screening visits and save on health care re-
sources without jeopardizing patient care. As the numbers of people diagnosed with
diabetes are rising, this can lead to challenges providing retinal screening. Themodel
could be used by the General Practices, which patientswith diabetes visit throughout
the year for routine blood tests and, in the event of a positive risk assessment, direct
them to the screening service.
5. Conclusions and future perspectives
In this work we presented a model for the identification of people with diabetes at
risk of developing diabetic retinopathy. In the future, we aim to investigate whether
additional information, e.g., co-morbidities, ethnicity, andmedicationcouldenhance
the predictive ability of the model.
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